Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome.

In this study, we report an angiopep-2 modified cationic liposome (ANG-CLP) for the efficient co-delivery of a therapeutic gene encoding the human tumour necrosis factor-related apoptosis-inducing ligand (pEGFP-hTRAIL) and paclitaxel (PTX) to glioma. The dual targeting co-delivery system (ANG-CLP/PTX/pEGFP-hTRAIL) improved uptake and gene expression not only in U87 MG cells and BCECs, but also in the glioma bed and infiltrating margin of intracranial U87 MG glioma-bearing models. The system selectively induces apoptosis in U87 MG cells while reducing toxicity to BCECs. The results of the pharmacodynamics studies showed that the apoptosis of glioma cells in in vitro BBB models and in U87 MG glioma-bearing mice induced by ANG-CLP/PTX/pEGFP-hTRAIL was more apparent and widespread than that induced by single medication systems and unmodified co-delivery system. More importantly, the median survival time of brain tumour-bearing mice treated with ANG-CLP/PTX/pEGFP-hTRAIL was 69.5 days, significantly longer than that of other groups, even longer than the commercial temozolomide group (47 days). Therefore, the dual targeting co-delivery system is a promising drug delivery strategy against glioma.

[1]  T. Park,et al.  Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. , 2010, Biomaterials.

[2]  Yen Wah Tong,et al.  Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. , 2009, Biomaterials.

[3]  Jijin Gu,et al.  Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. , 2010, International journal of pharmaceutics.

[4]  Xiaoling Fang,et al.  Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. , 2011, Biomaterials.

[5]  D. Fortin,et al.  Uptake and intracellular release kinetics of liposome formulations in glioma cells. , 2010, International journal of pharmaceutics.

[6]  Lucienne Juillerat-Jeanneret,et al.  The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? , 2008, Drug discovery today.

[7]  C. Hawkins.  TRAIL and malignant glioma. , 2004, Vitamins and hormones.

[8]  Chen Jiang,et al.  Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. , 2009, Biomaterials.

[9]  M. Berger,et al.  Convection-Enhanced Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand with Systemic Administration of Temozolomide Prolongs Survival in an Intracranial Glioblastoma Xenograft Model , 2004, Cancer Research.

[10]  Rongqin Huang,et al.  Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. , 2011, Biomaterials.

[11]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[12]  R. Sachs,et al.  Cancer drug resistance: the central role of the karyotype. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[13]  Vaishali Bagalkot,et al.  A combined chemoimmunotherapy approach using a plasmid-doxorubicin complex. , 2009, Molecular pharmaceutics.

[14]  O. Ogawa,et al.  TRAIL and chemotherapeutic drugs in cancer therapy. , 2004, Vitamins and hormones.

[15]  Wafik S El-Deiry,et al.  TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.

[16]  Feng Liu,et al.  Non‐immunostimulatory nonviral vectors , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  W. El-Deiry,et al.  TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. , 2008, Cancer research.

[18]  S. Curley,et al.  Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. , 2001, Cancer research.

[19]  M. Mizuno,et al.  Clinical Gene Therapy for Brain Tumors. Liposomal Delivery of Anticancer Molecule to Glioma , 2003, Journal of Neuro-Oncology.

[20]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[21]  H. Zentgraf,et al.  TNF‐α‐ and TRAIL‐resistant glioma cells undergo autophagy‐dependent cell death induced by activated microglia , 2009, Glia.

[22]  Ho Sup Yoon,et al.  Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer , 2006, Nature materials.

[23]  Nathan F. Bouxsein,et al.  Non-viral gene delivery with cationic liposome-DNA complexes. , 2008, Methods in molecular biology.

[24]  R. Béliveau,et al.  Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2 , 2008, British journal of pharmacology.

[25]  Chen Jiang,et al.  Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. , 2011, Biomaterials.

[26]  W. El-Deiry,et al.  Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells , 2009, Molecular Cancer Therapeutics.

[27]  H. Luhmann,et al.  Fluvastatin stabilizes the blood–brain barrier in vitro by nitric oxide-dependent dephosphorylation of myosin light chains , 2006, Neuropharmacology.